A carregar...
Ibrutinib in Gynecological Malignancies and Breast Cancer: A Systematic Review
Ibrutinib is an orally available, small-molecule tyrosine kinase inhibitor. Its main purpose is to inhibit Bruton’s tyrosine kinase (BTK), an enzyme that is crucial in B cell development. It is FDA approved for the treatment of certain hematological malignancies. Several promising off-target drug ef...
Na minha lista:
| Publicado no: | Int J Mol Sci |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7312555/ https://ncbi.nlm.nih.gov/pubmed/32532074 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21114154 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|